Financials
Financial year 2025
PENTAPHARMA from Veurne, company number BE0666417120, closed financial year 2025 with a result of € 2,769 after tax. For that financial year PENTAPHARMA recorded a gross margin of € 4,509 and equity of € 38,418. Compared with financial year 2024, the result moved from € 5,596 to € 2,769. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 13, 2026.
€ 38,418
▲ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2,769
▼ 51% vs 2024
Profit after tax over the fiscal year.
€ 20,656
▲ 158% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 18,418.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 17,798
▲ € 14,246 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 671
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 3,308 | € -37 | € 7,972 | € 4,509 | ▼ 43% |
| Profit after taxes | € 6,079 | € -655 | € 5,596 | € 2,769 | ▼ 51% |
| Equity | € 30,709 | € 30,053 | € 35,649 | € 38,418 | ▲ 8% |
| Total debts | € 51,896 | € 33,510 | € 41,649 | € 38,469 | ▼ 8% |
| Cash | € 49,397 | € 24,749 | € 8,010 | € 20,656 | ▲ 158% |
| Retained profit | € 10,709 | € 10,053 | € 15,649 | € 18,418 | ▲ 18% |
| Balance sheet total | € 82,605 | € 63,564 | € 77,298 | € 76,887 | ▼ 1% |
Key figures of PENTAPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PENTAPHARMA?
What happened at PENTAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 2,769 (▼ 51% vs 2024). Source: NBB ↗
- New establishment in Veurne. KBO
- Start of the company according to the CBE. KBO
In short
From € 6,079 profit in 2022 to € 2,769 profit in 2025.
Paid € 4,619 in corporate taxes since 2022.
Best year ever: 2022, with € 6,079 profit.
Management
The stake of UNIPHARM comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PENTAPHARMABehind PENTAPHARMA are Kristiaan TRYPSTEEN and UNIPHARM BV. The shares are held by UNIPHARM (20%).
Directors
According to the 2025 annual accounts
Kristiaan TRYPSTEEN
Director
Director · represented by Chris VANDENBERGHE
Shareholders
20%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Slableedstraat 2E
8630 Veurne
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0666.417.120
- VAT number
- BE 0666.417.120
- Registered office
- Slableedstraat 2E, 8630 Veurne
- Names & denominations
- PENTAPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 November 2016
- Peppol
- Active · Active since 17 Dec 2025
- Activities · NACE
Markt- en opinieonderzoek